Codiak BioSciences, Inc. CDAK
0.06 0.00 (+0.00%)
At closeApr 4, 2023, 4:00 PM EDT
0.0532 Day range 0.11
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 9.00
Ratings (-1m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 4
- 2 months ago 4
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.36 | -0.36 – -0.36 | 0.74 | -148.6% | 2.03M | -73.6% | 1 |
| Next quarter | -0.34 | -0.34 – -0.34 | -0.36 | +5.6% | 2.03M | -84.0% | 1 |
| Current year | -2.39 | -2.39 – -2.39 | -1.70 | -40.6% | 28.41M | +23.9% | 1 |
| Next year | -1.39 | -1.39 – -1.39 | -2.39 | +41.8% | 7.87M | -72.3% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Aug 31, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Jul 4, 2022 | Goldman Sachs | Maintained | — | Buy |
| May 23, 2022 | Goldman Sachs | Maintained | — | Buy |
| Feb 21, 2022 | Wedbush | Maintained | — | Outperform |
| Feb 10, 2022 | Goldman Sachs | Initiated | — | Buy |
| Nov 8, 2020 | Goldman Sachs | Initiated | — | Buy |
| Nov 8, 2020 | Wedbush | Initiated | — | Outperform |